B of A Securities Upgrades Axsome Therapeutics to Neutral, Raises Price Target to $81
Portfolio Pulse from richadhand@benzinga.com
B of A Securities analyst Jason Gerberry has upgraded Axsome Therapeutics (NASDAQ:AXSM) from Underperform to Neutral and raised the price target from $59 to $81.
August 08, 2023 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics has been upgraded to Neutral from Underperform by B of A Securities, with a raised price target from $59 to $81.
The upgrade from Underperform to Neutral by B of A Securities indicates a more positive outlook for Axsome Therapeutics. The raised price target from $59 to $81 suggests that the analyst sees potential for the stock's price to increase. This could lead to a positive short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100